

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

HIGH CONCENTRATION OF SHAREHOLDING

This announcement is made at the request of the Stock Exchange in respect of the high concentration of the shareholding of the Company in the hands of a limited number of Shareholders as at 20 November 2024.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares.

This announcement is made by Jinhai Medical Technology Limited (“**Company**”) at the request of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in respect of the high concentration of the shareholding of the Company in the hands of a limited number of shareholders of the Company (“**Shareholders**”) as at 20 November 2024.

HIGH CONCENTRATION OF SHAREHOLDING

The Company noted that an announcement (“**SFC Announcement**”) was published by the Securities and Futures Commission (“**SFC**”) on 9 December 2024.

As disclosed in the SFC Announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC’s findings suggested that, as at 20 November 2024, a group of 27 shareholders held an aggregate of 533,280,000 shares of the Company (“**Shares**”), representing 41.26% of the issued Shares. Such shareholding, together with 632,500,000 Shares (representing 48.94% of the issued Shares) held by the chairman and executive director of the Company, represented 90.20% of the issued Shares as at 20 November 2024. Therefore, only 126,720,000 Shares (representing 9.80% of the issued Shares) were held by other shareholders.

According to the SFC Announcement, as at 20 November 2024, the shareholding structure of the Company was as follows:

	Number of Shares held (Shares)	% of total number of issued Shares (%)
Mr. Chen Guobao (<i>Note 1</i>)	632,500,000	48.94
27 shareholders and their related parties	533,280,000	41.26
Other shareholders	126,720,000	9.80
Total	<u>1,292,500,000</u>	<u>100.00</u>

Note 1: Mr. Chen Guobao is the chairman and an executive director of the Company. Mr. Chen Guobao indirectly held 632,500,000 Shares through Full Fortune International Co., Limited, which he wholly owns.

It was stated in the SFC Announcement that, amongst others:

- (a) The closing price of the Shares rose from HK\$5.10 as at 13 September 2024 to HK\$9.06 as at 20 November 2024, representing a gain of 77.65%.
- (b) As at 6 December 2024, the Shares closed at HK\$8.50, representing an increase of 66.67% from the closing price of HK\$5.10 on 13 September 2024.

The information above is extracted from the SFC Announcement and the board (“**Board**”) of directors (“**Directors**”) of the Company has not independently verified such information. Accordingly, the Board is not in a position to comment on the accuracy of the above information except for (i) the shareholdings held by Full Fortune International Co., Ltd based on the latest available disclosure of interests notices filed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) the information set out in paragraphs (a) to (b) above. Please refer to the SFC Announcement for further details.

PUBLIC FLOAT

Based on the information available and to the Directors’ best knowledge after making all reasonable enquiries, the Directors confirm that not less than 25% of the issued Shares were held in public hands as at 20 November 2024 and the date of this announcement, and the Company has maintained a sufficient public float as required under the Rules Governing the Listing of Securities on the Stock Exchange.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares. Further, as a result of high concentration of shareholding, the Company's securities may not have a genuine market or its shareholding may have been concentrated in the hands of a few shareholders.

By order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman and Executive Director

Hong Kong, 9 December 2024

As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping and Mr. Dai Yong; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.